We are broadly interested in the biology of mycobacteria, which include the major human pathogen M. tuberculosis, the nonpathogenic model organism M. smegmatis, and the cancer biotherapeutic agent BCG.
Michael S. Glickman, MD
Research FocusPhysician-scientist Michael Glickman investigates the physiology and pathogenic mechanisms of mycobacteria, including regulated intramembrane proteolysis (the Rip1 pathway); double-strand-break repair and associated DNA damage responses; and cell envelope biosynthesis.
- MD, Columbia University College of Physicians and Surgeons
- Signal Transduction across the M. Tuberculosis Cell Envelope via Regulated Intramembrane Proteolysis
- Double-Strand Break Repair in Mycobacteria: Novel pathways of repair and response
- Mechanism of Action and Determinants of Response to BCG therapy in Bladder Cancer
- Biosynthesis and Pathogenic Role of the M. tuberculosis Cell Envelope
- Landry, D.W., Zhao, K., Yang, G.X., Glickman, M., and Georgiadis, T.M. 1993. Antibody- catalyzed degradation of cocaine. Science 259:1899-1901.
- Glickman, M., and Klein, R.S. 1997. Acute epiglottitis due to Pasteurella multocida in an adult without animal exposure. Emerg Infect Dis 3:408-409.